Log in

NASDAQ:NVAXNovavax Stock Price, Forecast & News

$170.29
+2.79 (+1.67 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$166.26
Now: $170.29
$178.56
50-Day Range
$59.27
MA: $110.11
$173.49
52-Week Range
$3.54
Now: $170.29
$189.40
Volume6.52 million shs
Average Volume7.67 million shs
Market Capitalization$9.87 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen. The company also develops RSV F vaccine for older adults in Phase II clinical trial, and healthy children between two and six years of age in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus in Phase I clinical trial, as well as MERS coronavirus in animals; and combination respiratory vaccine to protect against influenza and RSV. The company has a clinical development agreement with Bill & Melinda Gates Foundation. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Read More
Novavax logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.66 million
Book Value($5.75) per share

Profitability

Net Income$-132,690,000.00
Net Margins-638.76%

Miscellaneous

Employees373
Market Cap$9.87 billion
Next Earnings Date8/10/2020 (Confirmed)
OptionableOptionable
$170.29
+2.79 (+1.67 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novavax (NASDAQ:NVAX) Frequently Asked Questions

How has Novavax's stock been impacted by COVID-19 (Coronavirus)?

Novavax's stock was trading at $10.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVAX shares have increased by 1,520.3% and is now trading at $170.29.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Novavax?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Novavax
.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Novavax
.

How can I listen to Novavax's earnings call?

Novavax will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.67) by $0.09. The biopharmaceutical company had revenue of $3.38 million for the quarter, compared to analysts' expectations of $3.50 million. During the same quarter last year, the company posted ($2.20) earnings per share.
View Novavax's earnings history
.

When did Novavax's stock split? How did Novavax's stock split work?

Novavax shares reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for NVAX?

7 equities research analysts have issued 1-year target prices for Novavax's stock. Their forecasts range from $15.00 to $275.00. On average, they anticipate Novavax's stock price to reach $124.07 in the next twelve months. This suggests that the stock has a possible downside of 27.1%.
View analysts' price targets for Novavax
.

Has Novavax been receiving favorable news coverage?

Headlines about NVAX stock have been trending very positive on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novavax earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Novavax
.

Who are some of Novavax's key competitors?

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Cara Therapeutics (CARA), NVIDIA (NVDA) and AT&T (T).

Who are Novavax's key executives?

Novavax's management team includes the following people:
  • Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)
  • Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)
  • Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)
  • Dr. Gregory M. Glenn, Pres of R&D (Age 65)
  • Ms. Erika S. Trahan, Sr. Mang. of Investor & PR

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different institutional and retail investors. Top institutional investors include Swiss National Bank (0.20%), Creative Planning (0.16%), TSP Capital Management Group LLC (0.13%), Virtu Financial LLC (0.12%), New York State Common Retirement Fund (0.09%) and Mackay Shields LLC (0.05%). Company insiders that own Novavax stock include Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Rachel K King.
View institutional ownership trends for Novavax
.

Which major investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, Beirne Wealth Consulting Services LLC, UBS Group AG, and Leap Investments LP. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino, and Michael A Mcmanus Jr.
View insider buying and selling activity for Novavax
.

Which major investors are buying Novavax stock?

NVAX stock was acquired by a variety of institutional investors in the last quarter, including Swiss National Bank, Virtu Financial LLC, New York State Common Retirement Fund, Mackay Shields LLC, State Board of Administration of Florida Retirement System, Moody Aldrich Partners LLC, Rafferty Asset Management LLC, and Principal Financial Group Inc.. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax
.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $170.29.

How big of a company is Novavax?

Novavax has a market capitalization of $9.87 billion and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 373 workers across the globe.

What is Novavax's official website?

The official website for Novavax is www.novavax.com.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.